AMBALALSA vs SUDEEPPHRM: Stock Comparison
SUDEEP PHARMA is the larger company by market capitalisation. AMBALALSA shows a lower P/E, while SUDEEP PHARMA shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AMBALALSA leads 3; SUDEEPPHRM leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | AMBALALSA | SUDEEPPHRM |
|---|---|---|
| Live Price | ₹47.74 | ₹1,003.3 |
| Day Change | 3.07% | 0.26% |
| Volume | 2.46 L | 1.95 L |
| 52-Week High | ₹49.98 | ₹1,378 |
| 52-Week Low | ₹30.15 | ₹524.05 |
| Distance from 52W High | -4.48% | -27.19% |
Valuation
| Metric | AMBALALSA | SUDEEPPHRM |
|---|---|---|
| Market Cap | ₹303 Cr | ₹11,289 Cr |
| P/E Ratio | 27.1x | 61.74x |
| P/B Ratio | 2.22x | 12.78x |
| EPS | ₹0.52 | ₹3.59 |
| Book Value | ₹20.67 | ₹79.51 |
| Dividend Yield | 0% | 0.15% |
Growth
| Metric | AMBALALSA | SUDEEPPHRM |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | -33.48% | 0% |
| Qtr Profit Growth | -38.84% | 0% |
Profitability & Leverage
| Metric | AMBALALSA | SUDEEPPHRM |
|---|---|---|
| ROE | 18.48% | 19.41% |
| ROCE | 14.73% | 17.66% |
| Net Margin | 8.8% | 27.14% |
| Operating Margin | 262.56% | 36.7% |
| Debt to Equity | 0.19x | 0.17x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | AMBALALSA | SUDEEPPHRM |
|---|---|---|
| Promoter Holding | 31.36% | 76.15% |
| FII Holding | 0% | 2.93%▲ 1.12 pp |
| DII Holding | 0.01% | 14.05%▼ 1.6 pp |
| Public Holding | 68.64% | 6.87%▲ 0.48 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AMBALALSA and SUDEEP PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.